Labixiaoxin (01262) announced interim results
- RevenueRMB6.3bn
- Net profitRMB-17.7M
- Profit attributable to ownersRMB-17.7M
- Revenue YoY+21.8%
- Net profit YoY-800.1%
- Depreciation & amortisationHK$30.7M
- Capital expenditureHK$-86.4M
- Interest-bearing debtHK$5.2bn
Source Labixiaoxin



